HS
AMLX icon

HighVista Strategies’s Amylyx Pharmaceuticals AMLX Stock Holding History

HighVista Strategies’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.93M Buy
386,080
+33,995
+10% +$526K 1.58% 15
2026
Q1 		$4.89M Buy
352,085
+113,273
+47% +$1.59M 1.35% 14
2025
Q4 		$2.88M Buy
+238,812
New +$3.24M 0.74% 45
2024
Q1 		– Sell
-26,349
Closed -$388K – 134
2023
Q4 		$388K Hold
26,349
– – 0.14% 121
2023
Q3 		$482K Buy
26,349
+12,601
+92% +$266K 0.22% 112
2023
Q2 		$297K Buy
+13,748
New +$371K 0.14% 134

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

HighVista Strategies's AMLX Position: Q2 2026 in Review

HighVista Strategies increased its Amylyx Pharmaceuticals (AMLX) stake by 9.7% in Q2 2026, buying an estimated $526K and bringing the position to 386,080 shares worth $6.93M. The position accounts for 1.58% of the portfolio, ranked #15.

HighVista Strategies first reported a position in AMLX in Q2 2023 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • HighVista Strategies held 386,080 shares of Amylyx Pharmaceuticals worth $6.93M as of Q2 2026.
  • HighVista Strategies bought 33,995 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $526K.
  • Amylyx Pharmaceuticals made up 1.58% of HighVista Strategies's portfolio in Q2 2026, its #15 holding.
  • HighVista Strategies first reported a position in Amylyx Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.